Literature DB >> 22996784

[A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].

Kaname Yamashita1, Daisuke Ishikawa, Shigeki Nanjo, Shinji Takeuchi, Tadaaki Yamada, Hisatsugu Mouri, Koushiro Ohtsubo, Kazuo Yasumoto, Masashi Kumagai, Yoshimichi Ueda, Seiji Yano.   

Abstract

A 74-year-old woman diagnosed with poorly-differentiated neuroendocrine carcinoma originating from the ascending colon was referred to our hospital. She had felt anorexia, abdominal pains and her (ECOG) performance status was 3. Her CT scan showed that some abdominal lymph nodes were swelling and that there were many metastatic lesions occupying most of the liver. We started chemotherapy with cisplatin and irinotecan according to a regimen for small cell lung cancer. Considering her poor PS, both of the drugs were administered at 30mg/m² twice 4 weeks in the first course of chemotherapy. Her anorexia and abdominal pains immediately disappeared, and CT scan showed that all of the metastases were decreased in size. After 4 courses, however, some of the metastatic lesions were increased in size. She died 8 months after diagnosis. The tumor marker doubling time was 17 days.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996784

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  A case of an elderly patient with high-grade colorectal cancer in poor general condition who showed near complete response to chemotherapy and achieved long-term survival.

Authors:  Yoshiaki Kanemoto; Giichiro Tsurita; Tomohiro Kurokawa; Yuki Azuma; Kentaro Yazawa; Yoshinori Murakami
Journal:  Int J Surg Case Rep       Date:  2019-03-22

Review 2.  Colorectal neuroendocrine carcinoma: A case report and review of the literature.

Authors:  Tomoaki Yoshida; Kenya Kamimura; Kazunori Hosaka; Koji Doumori; Hiromitsu Oka; Akito Sato; Yasuo Fukuhara; Shoji Watanabe; Tomomi Sato; Akira Yoshikawa; Takashi Tomidokoro; Shuji Terai
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.